Why hospitals are making their own ChatGPTs for patient records
To make the most of his 30-minute appointments with patients, Penn Medicine Chief Health Information Officer Srinath Adusumalli…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Clemson Announces 2026 Football Schedule – Clemson Tigers Official Athletics Site
GAME-BY-GAME SATURDAY, SEPT. 5 • AT LSU • TIGER STADIUM, BATON ROUGE, LA. Clemson and LSU faced one…
Number of new U.S. drug shortages hits lowest level in 20 years
The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly…
OpenEvidence raises $250 million, doubling its valuation| STAT
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
We’re reading about Canada speeding drug reviews, Novo ads
Rise and shine, everyone, another busy day is headed your way. And it is getting off to a…
New FDA cell and gene therapy oversight system comes with risks
At a Food and Drug Administration cell and gene therapy (CGT) roundtable last June, most speakers pushed for…
Kaiser Permanente, DOJ settle Medicare Advantage fraud case
The Justice Department won its biggest Medicare Advantage fraud settlement yet on Wednesday, notching a $556 million deal…
How much Medicare stands to pay for FDA breakthrough devices
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Secretive Project Prometheus takes VC Bob Nelsen beyond just health care
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and…
At JPM 2026, top CMS officials face questions from health care execs
Tara Bannow covers hospitals, providers, and insurers. You can reach Tara on Signal at tarabannow.70. SAN FRANCISCO —…
Investor Noubar Afeyan warns against a backlash to science in the U.S.
SAN FRANCISCO — Noubar Afeyan, one of biotech’s top investors, warned in an annual letter that a backlash…